PAPER Dickerson F, Stallings C, Origoni A, Katsafanas E, Schweinfurth LA, Savage CL, Yolken R
SEARCH RESULTS
330883 RESULTS
PAPER Seeley WW, Matthews BR, Crawford RK, Gorno-Tempini ML, Foti D, Mackenzie IR, Miller BL
Unravelling Boléro: progressive aphasia, transmodal creativity and the right posterior neocortex.
Brain. 2008 Jan;131(Pt 1):39-49. Epub 2007 Dec 5 PubMed: 18057074Art as Therapy—Can Creative Expression Soothe Dementia Symptoms?
RESEARCH NEWS 2014-05-23 Research News With a final stroke of the brush, Laura Baxter puts finishing touches on her painting, a piece of abstract art others deem a masterpiece. Baxter was diagnosed with Alzheimer’s disease at age 62. Now 77, she cannot remember how to sign her na
PAPER Leitz T, Beck H, Stephan M, Lehmann WD, De Petrocellis L, Di Marzo V
Possible involvement of arachidonic acid and eicosanoids in metamorphic events in Hydractinia echinata (Coelenterata; Hydrozoa).
J Exp Zool. 1994 Aug 1;269(5):422-31. PubMed: 8057074PAPER Miller BL, Ponton M, Benson DF, Cummings JL, Mena I
Enhanced artistic creativity with temporal lobe degeneration.
Lancet. 1996 Dec 21-28;348(9043):1744-5. PubMed: 8973469PAPER Fornazzari L, Ringer T, Ringer L, Fischer CE
Preserved drawing in a sculptor with dementia.
Can J Neurol Sci. 2013 Sep;40(5):736-7. PubMed: 23968952Mary Jo LaDu, Leon Tai on Has ApoE’s Time Come as a Therapeutic Target?
COMMENT As APOE4 is basically the genetic risk factor for AD, it is heartening to see these two papers. The paper by Holtzman and collaborators is a characterization that leaves few questions unanswered. That plaque burden decreases with systemic delivery of an A
PAPER Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JR Jr, Heyman RA
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Nature. 1997 Mar 27;386(6623):407-10. PubMed: 9121558Henrietta Nielsen on Has ApoE’s Time Come as a Therapeutic Target?
COMMENT Both these studies are addressing the ApoE problem by using different strategies to alter ApoE concentrations. Liao and colleagues used a monoclonal mouse anti-ApoE antibody trying to sequester ApoE levels in plaque-bearing APP/PS1 mice at the age of 7 mo
Gary Landreth on Has ApoE’s Time Come as a Therapeutic Target?
COMMENT The report by Michaelson's lab provides further validation of the effects of the RXR agonist bexarotene in murine models related to AD. They have employed a mouse model in which the human ApoE genes are knocked into the murine locus and, unlike previ
Has ApoE’s Time Come as a Therapeutic Target?
RESEARCH NEWS 2014-05-23 Research News Although the ApoE4 allele represents the primary genetic risk factor for late-onset Alzheimer’s disease, few researchers have attempted to target it therapeutically. Exactly how the allele promotes AD is only gradually becoming clearer, and
PAPER Boehm-Cagan A, Michaelson DM
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.
J Neurosci. 2014 May 21;34(21):7293-301. PubMed: 24849361PAPER Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Betensky R, Wozniak DF, Hyman BT, Holtzman DM
Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.
J Neurosci. 2014 May 21;34(21):7281-92. PubMed: 24849360Watch Aβ Aggregate in Real Time Inside Cell’s Acid Vesicles
RESEARCH NEWS 2014-05-23 Research News Most studies on Aβ aggregation take place in test tubes. Does the peptide clump up differently inside a nerve cell? Researchers led by Gabriele Kaminski Schierle, University of Cambridge, U.K., have developed a combination of fluorescence-ba
PAPER Hamlin CR, Black AL, Opalek JT
Assay interference caused by powder from prepowdered latex gloves.
Clin Chem. 1991 Aug;37(8):1460. PubMed: 1868613Current Filters
No filters selected